Back to Search
Start Over
Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections
- Source :
- Advances in Therapy
- Publication Year :
- 2019
- Publisher :
- Springer Science and Business Media LLC, 2019.
-
Abstract
- Introduction The new direct acting antiviral (DAA) therapies are able to effectively treat chronic hepatitis C (CHC). This study elicited the preferences of CHC patients for treatment attributes of new DAAs. Methods An online discrete choice experiment survey was designed to collect data from adult CHC patients in the USA, UK, France, Germany, Spain, and Italy. Patients were asked to choose from alternative hypothetical DAA options, defined by differing levels of nine attributes [i.e., treatment duration, tablet count and packaging, cure rate, required office visits when on treatment, modifications to statins or to proton pump inhibitors (PPIs), and risks of diarrhea, headache and nausea]. Logistic regression was used to assess preference for the treatment options. Results A total of 328 patients with CHC completed the survey (USA, n = 227; European countries, n = 101), with a mean age of 47.7 years (SD = 14.4) and an average 11.2 years since CHC diagnosis; 51% of patients were female. More than half (60%) of the patients had treatment for CHC. Patients significantly preferred a DAA regimen with higher cure rate, shorter treatment duration, lower risks of diarrhea, headache, and nausea (all p
- Subjects :
- Chronic hepatitis C virus
Adult
Male
030213 general clinical medicine
medicine.medical_specialty
Nausea
Decision Making
Logistic regression
Antiviral Agents
Virus
03 medical and health sciences
0302 clinical medicine
Germany
Surveys and Questionnaires
Internal medicine
medicine
Humans
Pharmacology (medical)
ddc:610
Original Research
business.industry
Patient preferences
Patient Preference
General Medicine
Hepatitis C, Chronic
Middle Aged
United States
Rheumatology
Europe
Diarrhea
Regimen
Italy
Tolerability
Spain
030220 oncology & carcinogenesis
HCV
Infectious diseases
Drug Therapy, Combination
Female
Direct acting antiviral therapies
France
medicine.symptom
DDA
business
Direct acting
Subjects
Details
- ISSN :
- 18658652 and 0741238X
- Volume :
- 36
- Database :
- OpenAIRE
- Journal :
- Advances in Therapy
- Accession number :
- edsair.doi.dedup.....76f1f5ca14f016a565e7d656554a6afa